Waxman/Hatch Reform May Include Generic Exclusivity, PhRMA Warns GPhA
Executive Summary
The Pharmaceutical Research & Manufacturers of America may encourage discussions on whether 180-day generic exclusivity should be abolished if Congress reopens Waxman/Hatch